These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 34668850

  • 1. In vitro activity of bedaquiline against Mycobacterium avium complex.
    Litvinov V, Makarova M, Kudlay D, Nikolenko N, Mikhailova J.
    J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34668850
    [Abstract] [Full Text] [Related]

  • 2. Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
    Wang M, Men P, Zhang W, Wu J, Gu Y, Wang F, Huang H, Yu X, Duan H.
    J Glob Antimicrob Resist; 2024 Jun; 37():135-140. PubMed ID: 38561143
    [Abstract] [Full Text] [Related]

  • 3. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
    Cho EH, Huh HJ, Song DJ, Moon SM, Lee SH, Shin SY, Kim CK, Ki CS, Koh WJ, Lee NY.
    J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
    [Abstract] [Full Text] [Related]

  • 4. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China.
    Pang Y, Zheng H, Tan Y, Song Y, Zhao Y.
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
    [Abstract] [Full Text] [Related]

  • 5. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
    Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ.
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872065
    [Abstract] [Full Text] [Related]

  • 6. Difference in drug susceptibility distribution and clinical characteristics between Mycobacterium avium and Mycobacterium intracellulare lung diseases in Shanghai, China.
    Wang W, Yang J, Wu X, Wan B, Wang H, Yu F, Guo Y.
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [Abstract] [Full Text] [Related]

  • 7. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
    Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.
    J Antimicrob Chemother; 2019 Apr 01; 74(4):935-943. PubMed ID: 30649327
    [Abstract] [Full Text] [Related]

  • 8. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
    Zheng HW, Pang Y, He GX, Song YY, Zhao YL.
    Biomed Environ Sci; 2017 Jul 01; 30(7):517-525. PubMed ID: 28756811
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
    Martin A, Godino IT, Aguilar-Ayala DA, Mathys V, Lounis N, Villalobos HR.
    J Med Microbiol; 2019 Aug 01; 68(8):1137-1139. PubMed ID: 31210631
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
    Kim DH, Jhun BW, Moon SM, Kim SY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ.
    Antimicrob Agents Chemother; 2019 Aug 01; 63(8):. PubMed ID: 31182533
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
    Zhao X, Wang Y, Pang Y.
    Infect Genet Evol; 2014 Oct 01; 27():332-8. PubMed ID: 25131955
    [Abstract] [Full Text] [Related]

  • 12. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
    Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T.
    J Antimicrob Chemother; 2004 Oct 01; 54(4):755-60. PubMed ID: 15347635
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J, Pei Y, Yan X, Shi G, Li T, Gao M, Liu Y, Wang Y, Shu W, Li L, Pang Y.
    Int J Infect Dis; 2020 Nov 01; 100():196-198. PubMed ID: 32890726
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, China.
    Zhu R, Shang Y, Chen S, Xiao H, Ren R, Wang F, Xue Y, Li L, Li Y, Chu N, Huang H.
    Microbiol Spectr; 2022 Dec 21; 10(6):e0137222. PubMed ID: 36250885
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease.
    Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ.
    J Clin Microbiol; 2017 Feb 21; 55(2):574-584. PubMed ID: 27927925
    [Abstract] [Full Text] [Related]

  • 20. Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: Frequency, clinical importance, and molecular and phenotypic resistance profiles.
    Truden S, Žolnir-Dovč M, Sodja E, Starčič Erjavec M.
    Infect Genet Evol; 2020 Aug 21; 82():104311. PubMed ID: 32247868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.